PROS
MCID: PK3005
MIFTS: 34

Pik3ca-Related Overgrowth Syndrome (PROS)

Categories: Cardiovascular diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pik3ca-Related Overgrowth Syndrome

MalaCards integrated aliases for Pik3ca-Related Overgrowth Syndrome:

Name: Pik3ca-Related Overgrowth Syndrome 58
Pros 58

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


External Ids:

Orphanet 58 ORPHA530313

Summaries for Pik3ca-Related Overgrowth Syndrome

MalaCards based summary : Pik3ca-Related Overgrowth Syndrome, also known as pros, is related to pik3ca-related overgrowth spectrum and obesity, early-onset, with adrenal insufficiency and red hair. An important gene associated with Pik3ca-Related Overgrowth Syndrome is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Capecitabine and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate.

Related Diseases for Pik3ca-Related Overgrowth Syndrome

Diseases in the Overgrowth Syndrome family:

Eed-Related Overgrowth Ezh2-Related Overgrowth
Pik3ca-Related Overgrowth Spectrum Pik3ca-Related Overgrowth Syndrome

Diseases related to Pik3ca-Related Overgrowth Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1832)
# Related Disease Score Top Affiliating Genes
1 pik3ca-related overgrowth spectrum 11.9
2 obesity, early-onset, with adrenal insufficiency and red hair 11.8
3 acute monoblastic leukemia 11.4
4 megalencephaly-capillary malformation-polymicrogyria syndrome 11.4
5 seborrheic dermatitis 11.4
6 prolidase deficiency 11.4
7 lipoid congenital adrenal hyperplasia 11.4
8 factor xiii deficiency 11.4
9 bone giant cell tumor 11.3
10 tuftsin deficiency 11.1
11 megacystis-microcolon-intestinal hypoperistalsis syndrome 11.1
12 ectodermal dysplasia and immunodeficiency 2 11.1
13 steel syndrome 11.1
14 lambda 5 deficiency 11.1
15 factor v leiden thrombophilia 11.1
16 facial infiltrating lipomatosis 11.1
17 neuroblastoma 10.9
18 prostate cancer 10.9
19 lung cancer 10.9
20 cytokine deficiency 10.8
21 follicular lymphoma 10.7
22 overgrowth syndrome 10.5
23 ischemia 10.4
24 helix syndrome 10.4
25 colorectal cancer 10.4
26 autoimmune disease 10.4
27 toxic shock syndrome 10.4
28 heart disease 10.4
29 ovarian cancer 10.3
30 atherosclerosis susceptibility 10.3
31 lipoprotein quantitative trait locus 10.3
32 vascular disease 10.3
33 chronic kidney disease 10.3
34 pre-eclampsia 10.3
35 kidney disease 10.3
36 lung disease 10.3
37 breast cancer 10.3
38 inflammatory bowel disease 10.3
39 hyperlipoproteinemia, type iii 10.3
40 acute myocardial infarction 10.3
41 rapidly involuting congenital hemangioma 10.3
42 glioblastoma multiforme 10.3
43 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.3
44 arteries, anomalies of 10.3
45 proteasome-associated autoinflammatory syndrome 1 10.3
46 hepatocellular carcinoma 10.3
47 b-cell lymphoma 10.3
48 brittle bone disorder 10.3
49 periodontitis 10.3
50 alzheimer disease 10.3

Graphical network of the top 20 diseases related to Pik3ca-Related Overgrowth Syndrome:



Diseases related to Pik3ca-Related Overgrowth Syndrome

Symptoms & Phenotypes for Pik3ca-Related Overgrowth Syndrome

Drugs & Therapeutics for Pik3ca-Related Overgrowth Syndrome

Drugs for Pik3ca-Related Overgrowth Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Durvalumab Approved, Investigational Phase 4 1428935-60-7
6
Zinc Approved, Investigational Phase 4 7440-66-6 32051
7
Glucagon Approved Phase 4 16941-32-5
8
Gliclazide Approved Phase 4 21187-98-4 3475
9
Insulin glargine Approved Phase 4 160337-95-1
10
Lixisenatide Approved Phase 4 320367-13-3
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
14 Cholinergic Agents Phase 4
15 Tolterodine tartrate Phase 4 124937-52-6
16 Muscarinic Antagonists Phase 4
17 Cholinergic Antagonists Phase 4
18 Neurotransmitter Agents Phase 4
19 Gastrointestinal Agents Phase 4
20 Central Nervous System Stimulants Phase 4
21 Nicotinic Agonists Phase 4
22 Proton Pump Inhibitors Phase 4
23 Antacids Phase 4
24 Anti-Ulcer Agents Phase 4
25 Anesthetics Phase 4
26 Glucagon-Like Peptide 1 Phase 4
27 Insulin, Long-Acting Phase 4
28 Anesthetics, Local Phase 4
29 Insulin, Globin Zinc Phase 4
30 insulin Phase 4
31 Hypoglycemic Agents Phase 4
32
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
33
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
34
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
35
Midodrine Approved Phase 2, Phase 3 133163-28-7, 42794-76-3 4195
36
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
37
leucovorin Approved Phase 3 58-05-9 6006 143
38
Nintedanib Approved Phase 3 656247-17-5 56843413
39
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
40
Hydroxychloroquine Approved Phase 3 118-42-3 3652
41
Sulfasalazine Approved Phase 3 599-79-1 5353980 5359476
42
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
43
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
44
Testosterone Approved, Experimental, Investigational Phase 2, Phase 3 58-22-0, 481-30-1 10204 6013
45
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
46
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
47
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
48
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
49
Fluorouracil Approved Phase 3 51-21-8 3385
50
Gemcitabine Approved Phase 3 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 440)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
2 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ) Completed NCT00836381 Phase 4 Tolterodine extended-release (ER) 4mg;Placebo
3 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
4 An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
5 Identifying Optimal, Translatable Smoking Cessation Intervention Components Completed NCT01122238 Phase 4 Nicotine Patch;Nicotine Gum;Nicotine Patch + Nicotine Gum
6 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
7 Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab Recruiting NCT04381494 Phase 4
8 Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial) Recruiting NCT03819790 Phase 4 Basal insulin glargine and lixisenatide;Basal insulin Basaglar/Lantus + gliclazide MR;Metformin
9 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 pazopanib or guideline conform chemotherapy
10 Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery Recruiting NCT03638960 Phase 4 Bupivacaine liposome;Bupivacaine Hydrochloride
11 An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis Active, not recruiting NCT03589105 Phase 4 Ocrelizumab 300 mg;Ocrelizumab 600 mg
12 A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients. Terminated NCT02343159 Phase 4 dimethyl fumarate
13 Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial Terminated NCT00394303 Phase 4 Intraoperative continuous insulin infusion
14 A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) Withdrawn NCT02090348 Phase 4 dimethyl fumarate
15 Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04 Unknown status NCT00207636 Phase 3
16 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
17 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Unknown status NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
18 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis Completed NCT03912259 Phase 3 dupilumab SAR231893;placebo;Emollient (moisturizer)
19 A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
20 New Acute Treatment for Stroke - The Effect of Remote PERconditioning Completed NCT00975962 Phase 3 Actilyse
21 A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists Completed NCT01709578 Phase 3 Sarilumab;placebo;hydroxychloroquine;methotrexate;sulfasalazine;leflunomide
22 Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt. Completed NCT00817206 Phase 3 LCP-Tacro;Prograf
23 Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant Completed NCT01187953 Phase 3 Prograf (tacrolimus);LCP-Tacro
24 Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2) Completed NCT01327495 Phase 2, Phase 3 Testosterone 1% gel 1.25 g;Testosterone 1% gel 2.5 g;Testosterone 1% gel 5.0 g;testosterone 1% gel 10 g;testosterone 1% gel 15 g;Acyline
25 Telephone and Web-based Teen Tobacco Cessation in HMOs Completed NCT00311948 Phase 3
26 Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models Completed NCT00876941 Phase 3
27 ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS Recruiting NCT03645057 Phase 3 Crisaborole;Tacrolimus 0.03% Ointment
28 A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Recruiting NCT03928184 Phase 3 Lorecivivint;Placebo
29 Clinical, Radiological and Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant Recruiting NCT02336009 Phase 2, Phase 3
30 Multicenter Randomized Study on the Efficacy of Intravenous Iron Injection in Cancer Patients With Anemia Recruiting NCT04187716 Phase 3 Ferinject
31 A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT03782376 Phase 3 Ustekinumab approximately 6 mg/kg (IV);Placebo (SC);Placebo (IV);Ustekinumab 90 mg (SC) Group 1;Ustekinumab 90 mg (SC) Group 2
32 Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
33 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma Active, not recruiting NCT02948959 Phase 3 Dupilumab;Placebo;Asthma Controller Therapies (incl. prednisone/prednisolone);Asthma Reliever Therapies
34 A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease Active, not recruiting NCT03464136 Phase 3
35 A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands Active, not recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
36 A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Not yet recruiting NCT04385303 Phase 3 Lorecivivint;Placebo
37 A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma Not yet recruiting NCT04181827 Phase 3 JNJ-68284528;Pomalidomide;Bortezomib;Dexamethasone;Daratumumab
38 A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Not yet recruiting NCT04396860 Phase 2, Phase 3 Temozolomide
39 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
40 The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients Unknown status NCT02599012 Phase 2 Ferinject®
41 Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer Unknown status NCT00839865 Phase 2 herb ointment
42 Adaptation and Evaluation of the Honest Open Proud Program for Adolescents With Mental Illness Completed NCT02751229 Phase 2
43 Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation Completed NCT02428296 Phase 2 Sirolimus
44 BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study Completed NCT00828308 Phase 2 Ixabepilone
45 HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care Completed NCT01312181 Phase 2
46 Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice Completed NCT01108315 Phase 1, Phase 2
47 Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse Completed NCT00685074 Phase 1, Phase 2
48 Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer Completed NCT01334983 Phase 2
49 A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682) Completed NCT02469298 Phase 2 GSK1325756 (Danirixin);Placebo To Match GSK1325756;Oseltamivir Phosphate;Placebo To Match Oseltamivir Phosphate
50 Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT01854255 Phase 2 doxorubicin and cisplatin

Search NIH Clinical Center for Pik3ca-Related Overgrowth Syndrome

Genetic Tests for Pik3ca-Related Overgrowth Syndrome

Anatomical Context for Pik3ca-Related Overgrowth Syndrome

MalaCards organs/tissues related to Pik3ca-Related Overgrowth Syndrome:

40
Breast, Testes, Prostate, Lung, Heart, Brain, Kidney

Publications for Pik3ca-Related Overgrowth Syndrome

Articles related to Pik3ca-Related Overgrowth Syndrome:

(show top 50) (show all 10673)
# Title Authors PMID Year
1
The effect of postoperative femoral offset on outcomes after hip arthroplasty: A systematic review. 61
32273666 2020
2
Therapeutic ultrasound experiments in vitro: Review of factors influencing outcomes and reproducibility. 61
32402858 2020
3
Counselling for prenatal anomaly screening-A plea for integration of existential life questions. 61
32268986 2020
4
May Bioelectrical Impedance Analysis Method Be Used in Alternative to the Dual-Energy X-Ray Absorptiometry in the Assessment of Fat Mass and Fat-Free Mass in Patients with Obesity? Pros, Cons, and Perspectives. 61
32297081 2020
5
The Effect of Preoperative Symptom Duration on Postoperative Outcomes After Minimally Invasive Transforaminal Lumbar Interbody Fusion. 61
31503049 2020
6
Development and Evaluation of a Cancer Literacy Intervention to Promote Mammography Screening Among Navajo Women: A Pilot Study. 61
31986899 2020
7
Sarcopenia: Current treatments and new regenerative therapeutic approaches. 61
32489859 2020
8
Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. 61
32503791 2020
9
Recent advances in photoacoustic contrast agents for in vivo imaging. 61
32027784 2020
10
Anthocyanins: New techniques and challenges in microencapsulation. 61
32466932 2020
11
Effects on patient-reported outcomes of "Screening of Distress and Referral Need" implemented in Dutch oncology practice. 61
31781949 2020
12
Outcomes of Expandable Interbody Devices in Lumbar Fusion: A Systematic Review and Meta-analysis. 61
32101992 2020
13
Magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: pros and cons. 61
32398565 2020
14
Safety and feasibility of various fasting-mimicking diets among people with multiple sclerosis. 61
32408153 2020
15
The CoV-2 outbreak: how hematologists could help to fight Covid-19. 61
32387301 2020
16
During the COVID-19 pandemic, should nurses offer to pray with patients? 61
32558790 2020
17
The pros and cons of traditional Chinese medicines in the treatment of COVID-19. 61
32371086 2020
18
The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. 61
32400924 2020
19
Effects of surgery on the patient-reported outcomes of primary hyperparathyroidism patients with mild hypercalcemia without classic symptoms: a systematic review of the literature. 61
31165923 2020
20
Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury. 61
32554488 2020
21
Prospective longitudinal cohort study of patient recovery after major gastrointestinal surgery: is there a difference between minimally invasive and open approaches? 61
31586248 2020
22
Patient-Reported Outcomes (PROs) in Acute Symptomatic Seizure (ASyS) Versus Patients With Established Epilepsy. 61
32549943 2020
23
Pros and cons of pre-emptive screening programmes before peanut introduction in infancy. 61
32562634 2020
24
[Grey zones on dual antiplatelet therapy. Expert opinion]. 61
32555572 2020
25
Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results. 61
31665477 2020
26
Effect of alcohol consumption on patient-reported outcomes in hip arthroscopy: a matched controlled study with minimum 2-year follow-up. 61
31167582 2020
27
A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. 61
32298994 2020
28
Asymptomatic ACDF Nonunions Underestimate the True Prevalence of Radiographic Pseudarthrosis. 61
32080012 2020
29
Nanofibers as advanced sorbents for on-line solid phase extraction in liquid chromatography: A tutorial. 61
32493593 2020
30
Data from national media reports of 'Acid attacks' in England: A new piece in the Jigsaw. 61
31780279 2020
31
Diagnostic challenges of central nervous system infection: extensive multiplex panels versus stepwise guided approach. 61
31899336 2020
32
A meta-analysis of the pros and cons of partial superficial parotidectomy versus superficial parotidectomy for the treatment of benign parotid neoplasms. 61
32362539 2020
33
The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. 61
31971467 2020
34
High-altitude mountain telemedicine. 61
32539486 2020
35
Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography. 61
32100607 2020
36
Machine learning with PROs in breast cancer surgery; caution: Collecting PROs at baseline is crucial. 61
32160651 2020
37
Adopting PROs in virtual and outpatient management of RA. 61
32504074 2020
38
The Digital Transformation of Patient-Reported Outcomes' (PROs) Functionality Within Healthcare. 61
32570542 2020
39
Pros and cons of prosent as an alternative to traditional consent in medical research. 61
32571849 2020
40
The pros and cons of digital health communication tools in neurosurgery: a systematic review of literature. 61
30334173 2020
41
Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. 61
32533435 2020
42
Randomized comparative study of child and caregiver responses to three software functions added to the Japanese version of the electronic Pediatric Quality of Life Inventory (ePedsQL) questionnaire. 61
32577921 2020
43
Understanding patient motivations for HIV pre-exposure prophylaxis initiation and adherence. 61
31453828 2020
44
First-in-human dose: current status review for better future perspectives. 61
32488334 2020
45
How to choose your study design. 61
32479703 2020
46
Hopeful struggling for health: Experiences of participating in computerized cognitive training and aerobic training for persons with stress-related exhaustion disorder. 61
31995652 2020
47
Lithium-ion batteries towards circular economy: A literature review of opportunities and issues of recycling treatments. 61
32250918 2020
48
Comparison of implant position and joint awareness between fixed- and mobile-bearing unicompartmental knee arthroplasty: a minimum of five year follow-up study. 61
32577875 2020
49
Approximation of bias and mean-squared error in two-sample Mendelian randomization analyses. 61
31651042 2020
50
Consensus for experimental design in electromyography (CEDE) project: Amplitude normalization matrix. 61
32569878 2020

Variations for Pik3ca-Related Overgrowth Syndrome

Expression for Pik3ca-Related Overgrowth Syndrome

Search GEO for disease gene expression data for Pik3ca-Related Overgrowth Syndrome.

Pathways for Pik3ca-Related Overgrowth Syndrome

GO Terms for Pik3ca-Related Overgrowth Syndrome

Sources for Pik3ca-Related Overgrowth Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....